Showing 691-700 of 8927 results for "".
DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eDermWireTV: Cutera, Galderma Acne Treatments; Alma's TED; Diversity Initiatives
https://practicaldermatology.com/topics/practice-management/dermwiretv-cutera-galderma-acne-treatments-almas-ted-diversity-initiatives/20084/There are two new options for treating acne. Cutera introduces the AviClear acne device; Galderma launches Twyneo Cream. Joshua Zeichner, MD weighs in. Lady Dy, MD discusses Alma’s TED device, a non-invasive, non-traumatic option to address hair loss. New initiatives announced at or in conjunction wDermWireTV: Arcutis Takes PASI HD; Galderma at Camp Wonder; Amgen Challenge; LaRoche-Posay Pride
https://practicaldermatology.com/topics/psoriasis/dermwiretv-arcutis-takes-pasi-hd-galderma-at-camp-wonder-amgen-challenge-laroche-posay-pride/19996/The PASI high discrimination or PASI-HD tool was developed by Arcutis Biotherapeutics in collaboration with a panel of psoriasis research experts. Led by Amgen, in partnership with the International Federation of Psoriasis Associations, the Understanding Psoriatic Disease Leveraging Insights for TreHair Care Trends You Need to Know
https://practicaldermatology.com/conferences/aad-summer-2021/hair-care-trends-you-need-to-know/19976/People are sharing more than their latest dance moves on TikTok. Many—with no background in science—are dispensing hair care advice, some of which could even be dangerous. Learn which trends you should know about in order to educate your patients about what really works versus what could do more harManaging Advanced Skin Cancers
https://practicaldermatology.com/conferences/aad-2021/managing-advanced-skin-cancers/19920/Treatment of advanced NMSC can be a challenge, but therapeutic options continue to expand. Todd Schlesinger, MD discusses real-world use of hedgehog inhibitors—including modified regimens and adjuvant use—and PD-1 inhibitors for advanced disease.AK Therapy: Real-life Approaches to Combinations on Scientifically Speaking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-therapy-real-life-approaches-to-combinations-on-scientifically-speaking/19913/From serial PDT to novel combinations, specialists describe how they treat AKs in real-world settings. Scientifically Speaking host Joel L. Cohen, MD reviews cases from Neal Bhatia, MD, Michael H. Gold, MD, and George Martin, MD.DermWireTV: Pulse's CellFX, Soliton's RAP Technology, Belotero Balance (+), Restylane Defyne, Eczema Costs
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pulses-cellfx-solitons-rap-technology-belotero-balance-restylane-defyne-eczema-costs/19899/The FDA has cleared Pulse Biosciences’ CellFX system, and a commercial rollout will begin soon. There’s another new option for treatment for legs with FDA clearance of Soliton’s Rapid Acoustic Pulse technology for cellulite. For eight percent of Americans with atopic dermatitis, annual out of pocketPatient Assessment: A Key to AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/patient-assessment-a-key-to-ad-care/19889/What is the Quality of Care in Atopic Dermatitis initiative, and why is it important? Dr. Stephan Weidinger shares his thoughts on the importance of this "impressive" program and offers suggestions to improve the assessment and care of patents with eczema.ILUMYA SUPPORT™ patient access for commercial and Medicare Part B patients
https://practicaldermatology.com/topics/psoriasis/ilumya-support-patient-access-for-commercial-and-medicare-part-b-patients/19860/ILUMYA SUPPORT™ offers comprehensive programs and services to help patients start and stay on therapy with ILUMYA™. Learn about the three main patient access programs offered by ILUMYA SUPPORT™: the Early Access Program, the Co-pay Program, and the Patient Assistance Program. ILUMYA™ is reimbursed uDermWireTV: Cassiopeia Winlevi; Psoriasis Guidelines; Cyndi Lauper's PsO in the Know; Sarah Michelle Gellar's CoolSculpting
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cassiopeia-winlevi-psoriasis-guidelines-cyndi-laupers-pso-in-the-know-sarah-michelle-gellars-coolsculpting/19852/The FDA has approved Winlevi (Clascoterone cream 1%) from Cassiopea for the treatment of acne in patients 12 years and older.New Guidelines of care for the Management of Psoriasis with Systemic Nonbiologic Therapies, jointly issued by the American Academy of Dermatology and the National Psoriasis Fo